Zhang Chun, Peng Zheng, Ban DeYing, Zhang Yi
1 Department of Obstetrics and Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Reprod Sci. 2018 Mar;25(3):443-451. doi: 10.1177/1933719117715123. Epub 2017 Jun 29.
In this study, we investigated the expression of interleukin 35 (IL-35) and its receptors in endometriosis, analyzed the function of IL-35 in primary culture model of endometrial stromal cells (ESCs), and evaluated their clinicapathological significance. Peripheral blood (PB) and peritoneal fluid (PF) were collected from 37 women with endometriosis and 24 control women. The ectopic endometrium was obtained from patients with endometriosis undergoing laparoscopic surgery. The eutopic and normal endometrium were collected by endometrial biopsy. Levels of IL-35 in PB and PF were evaluated by enzyme-linked immunosorbent assay. Women with endometriosis had higher levels of IL-35 compared to controls both in PB and in PF. Levels of n IL-35 were increased in patients with advanced stage endometriosis compared to those with early stages in PF. A significant upregulation of IL-35 was observed in patients with ovarian endometriosis accompanied with pelvic implants (PI) compared to those without PI in PB and PF. The relative messenger RNA and protein expression of EBi3 and p35, the subunits of IL-35, were significantly higher in ectopic endometrium than in eutopic and healthy endometrium as measured by immunohistochemistry and quantitative polymerase chain reaction. The ESCs from endometriosis displayed a remarkable overexpression of IL-35 receptor subunits, IL12Rβ2 and gp130, compared to those from controls . Moreover, recombined human IL-35 protein stimulated the upregulation of IL12Rβ2 and gp130 and facilitated proliferation of ESCs. Our study provides the first evidence that IL-35 was involved in the pathogenesis of endometriosis through suppressing immunoreaction and promoting proliferation of ESCs. IL-35 may potentially serve as a biomarker for endometriosis.
在本研究中,我们调查了白细胞介素35(IL-35)及其受体在子宫内膜异位症中的表达,分析了IL-35在子宫内膜基质细胞(ESC)原代培养模型中的功能,并评估了它们的临床病理意义。收集了37例子宫内膜异位症患者和24例对照女性的外周血(PB)和腹腔液(PF)。从接受腹腔镜手术的子宫内膜异位症患者中获取异位子宫内膜。通过子宫内膜活检收集在位和正常子宫内膜。采用酶联免疫吸附测定法评估PB和PF中IL-35的水平。与对照组相比,子宫内膜异位症患者的PB和PF中IL-35水平更高。在PF中,晚期子宫内膜异位症患者的IL-35水平高于早期患者。与无盆腔植入物(PI)的患者相比,伴有盆腔植入物的卵巢子宫内膜异位症患者的PB和PF中IL-35显著上调。通过免疫组织化学和定量聚合酶链反应检测,IL-35的亚基EBi3和p35在异位子宫内膜中的相对信使核糖核酸和蛋白表达显著高于在位和健康子宫内膜。与对照组相比,来自子宫内膜异位症的ESC显示出IL-35受体亚基IL12Rβ2和gp130的显著过表达。此外,重组人IL-35蛋白刺激了IL12Rβ2和gp130的上调,并促进了ESC的增殖。我们的研究首次证明IL-35通过抑制免疫反应和促进ESC增殖参与子宫内膜异位症的发病机制。IL-35可能潜在地作为子宫内膜异位症的生物标志物。